Biotech News
Praxis Precision Medicines Details Launch Readiness for Relutrigine and Ulixacaltamide and Outlines Expanded Pipeline in Preparation to be the Preeminent CNS Biotech at Investor Day
Detailed launch readiness for relutrigine and ulixacaltamide, with PDUFA target action dates of December 27, 2026 and January 29, 2027 Shared updated long-term efficacy data for both relutrigine and ulixacaltamide Outlined plans to extend ulixacaltamide into Parkinson’s disease, Restless Legs
